Navigation Links
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Date:9/22/2008


Toronto Stock Exchange Symbol: MS

- US$10 million received based on the positive review of interim

analysis for international pivotal multiple sclerosis trial -

EDMONTON, Sept. 22 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company.

The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the Company's pivotal phase II/III Canadian and European trial (MAESTRO-01) of dirucotide (MBP8298) in patients with secondary progressive MS. The independent Data Safety Monitoring Board (DSMB) for the MAESTRO-01 trial recommended that the trial proceed to completion based on the interim analysis which included efficacy and safety data from the first 200 patients to complete the trial.

To date, BioMS has received a total of US$97 million in payments from Eli Lilly and Company, based on the licensing and development agreement for dirucotide (MBP8298). An additional $400 million in milestone payments are possible under the terms of the licensing agreement, in addition to escalating royalties on sales.

"We are pleased that our partner has recognized the outcome of the interim analysis as a significant positive event," said Kevin Giese, President and CEO of BioMS Medical. "We look forward to completing the MAESTRO-01 trial and reviewing the complete data set in the second half of 2009."

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
2. BioMS Medical to present at UBS Global Life Sciences Conference
3. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. BioMS Medical Announces Second Quarter 2008 Results
7. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
8. BioMS Medical to present at BMO Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at Jefferies Healthcare Conference
11. BioMS Medical to present at 2008 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Dr. Ingrid Warmuth and Anamaria Newport, MHS, PA-C, ... to announce an Open House at their Swedesboro location, 95 ... 8th from 10 AM to 2 PM. , During ... staff will be on hand to talk to people about ... provide complimentary cosmetic consultations. There will also be specials offered, ...
(Date:5/24/2013)... -- Senomyx , Inc. (NASDAQ: SNMX ... discover, develop, and commercialize novel flavor ingredients, announced today ... Company,s Vice President, Biology and Gwen Rosenberg ... will present an overview of Senomyx,s technology and programs ... (7:25 a.m. Pacific Time) during the Citi 2013 Global ...
(Date:5/24/2013)... 24, 2013 Vestiage, Inc. (stock ... focused on science-based research and development, sales and ... and nutraceuticals, announced today that it is awarding ... the sale of Reluma Skin Illuminating Facial Care. ... application by sending an email to info(at)vestiageinc(dot)com and ...
(Date:5/23/2013)... ROCK, Colo. , May 23, 2013 ... diagnostic company focused on obtaining FDA clearance and ... , today announced the pricing of an underwritten public ... related warrants to purchase 3,500,000 shares of its common ... at a combined public offering price of $1.25 per ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... markets, the trend in health care employment could be counted on ... bringing yearly growth up over 345,000.The MedZilla.com Employment Report analyzes the ... ... Seattle, WA (Vocus) December 3, 2008 -- The U.S. economy ...
... and HOUSTON, Dec. 2 Transgenomic,Inc. (OTC ... Inc. (OTC,Bulletin Board: PWRM) today announced that ... acquire exclusive rights for Power3 Medical,s Neurodegenerative,Biomarkers, ... Alzheimer,s,and Parkinson,s disease. Transgenomic plans to ...
... postmenopause , , MONTVALE, N.J., ... symptoms is a challenge for women experiencing menopause. OBG ... have recently published a supplement titled Vasomotor symptoms: Managing ... James McGregor, MD, CM and Lee P. Shulman, MD, discuss ...
Cached Biology Technology:The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4
(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... honored more than 165 staff for their creation, ... annual Intellectual Property Commercialization Recognition & Rewards Program ... laboratory named materials scientist Jun Liu Inventor of ... that can store large amounts of energy, ease ... time it takes to charge cell phones, electric ...
(Date:5/23/2013)... the overall health, development, and academic success of ... ensuring that all students have opportunities to engage ... vigorous or moderate-intensity physical activity, says a new ... estimates suggest that only about half of school-age ... health and development. The report recommends that ...
Breaking Biology News(10 mins):Please do try this at home 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3
... German . , In emerging countries such as ... consumption of red meat has quadrupled since 1961. The United ... lead to a doubling of global meat production by the ... limited farmland resources, will still be able to meet all ...
... DECEMBER 30, 2010 A recent study by a team ... incident of pathogens in biosolids over a 19 year period ... researchers also analyzed pathogen levels in biosolids at 18 wastewater ... analysis indicates pathogens levels have dropped since the implementation of ...
... you know that when you pick up a product promoted ... significant amount of this potentially harmful substance? An article by ... published in the January/February 2011 issue of the American ... can result in medically significant intake of harmful trans fat, ...
Cached Biology News:Eating low-fat, thanks to lupin proteins 2Wastewater treatment lowers pathogen levels 2Call for truth in trans fats labeling by the FDA 2
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Direct ELISA Assay Diluent, 10 L...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
Biology Products: